Intravenous Zoledronate 4 mg for the treatment of post-menopausal osteoporosis: A prospective open-labeled study

BACKGROUND: Zoledronate 5 mg intravenous (IV) annually is approved for treatment of post-menopausal osteoporosis. Zoledronate 4 mg which is approved for the treatment of cancer related hypercalcemia can be an alternative for Asian women who have smaller stature. OBJECTIVES: To examine the efficacy a...

Descripción completa

Detalles Bibliográficos
Autores principales: Arunthanachaikul, Thunyawarin, Chaiamnuay, Sumapa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Full Length Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651995/
https://www.ncbi.nlm.nih.gov/pubmed/34926731
http://dx.doi.org/10.1016/j.bonr.2021.101153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651995/
https://www.ncbi.nlm.nih.gov/pubmed/34926731
http://dx.doi.org/10.1016/j.bonr.2021.101153

Ejemplares similares